As Bayer waits, Cipla head says India needs compulsory licensing to break pharma monopolies
This article was originally published in Scrip
Cipla's chairman, Dr Yusuf Hamied, has questioned the Indian government's rationale of trying to link price negotiations for patented drugs using a reference pricing model and compulsory licensing. His comments come as a decision on Bayer’s appeal against the 2012 compulsory licensing of its cancer drug, Nexavar, is due from India's Intellectual Property Appellate Board on 4 March.
You may also be interested in...
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.